Corticosteroids/ other combinations - Resultados da pesquisa

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

dexaval a 1 mg/g + 10 mg/g creme

tecnifar - indústria técnica farmacêutica, s.a. - dexametasona + clorofenamina - creme - 1 mg/g + 10 mg/g - clorofenamina, maleato 11 mg/g ; dexametasona, valerato 1.05 mg/g - corticosteroids, moderately potent, combinations with antibiotics - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

dexaval v 1 mg/g + 30 mg/g creme

tecnifar - indústria técnica farmacêutica, s.a. - dexametasona + clioquinol - creme - 1 mg/g + 30 mg/g - dexametasona, valerato 1.05 mg/g ; clioquinol 33 mg/g - corticosteroids, dermatological preparations - n/a - duração do tratamento: curta ou média duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

vibrocil actilongprotect 1 mg/ml + 50 mg/ml solução para pulverização nasal

glaxosmithkline consumer healthcare produtos para a saúde e higiene lda. - xilometazolina + dexpantenol - solução para pulverização nasal - 1 mg/ml + 50 mg/ml - dexpantenol 50 mg/ml ; xilometazolina, cloridrato 1 mg/ml - dexpanthenolr01ab06 - xylometazoline - n/a - duração do tratamento: curta ou média duração

União Europeia - português - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azathioprine - rejeição de enxerto - imunossupressores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

União Europeia - português - EMA (European Medicines Agency)

imraldi

samsung bioepis nl b.v. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; hidradenitis suppurativa; arthritis - imunossupressores - artrite arthritisimraldi em combinação com metotrexato, é indicado para o tratamento de moderada a severa, artrite reumatóide activa em pacientes adultos, quando a resposta a modificadores da doença drogas anti-reumáticas, incluindo o metotrexato tem sido inadequados. o tratamento de graves, ativa e progressiva, a artrite reumatóide em adultos não previamente tratados com metotrexato. imraldi pode ser administrado como monoterapia em caso de intolerância ao metotrexato ou quando a continuidade do tratamento com metotrexato é inadequados. adalimumab tem sido mostrado para reduzir a taxa de progressão do dano articular, como medido por raio-x e para melhorar a função física, quando administrado em combinação com metotrexato. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisimraldi in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). imraldi can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab não foi estudado em pacientes com idade inferior a 2 anos. enthesitis-related arthritisimraldi is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asimraldi is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and / or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriática arthritisimraldi é indicado para o tratamento da artrite psoriática activa e progressiva em adultos, quando a resposta à anterior doença anti-reumáticas terapia de droga tem sido inadequada. adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5. 1) e para melhorar a função física. psoriasisimraldi é indicado para o tratamento de moderada para severa psoríase crónica em placas em pacientes adultos que são candidatos à terapia sistêmica,. pediátrica placa psoriasisimraldi é indicado para o tratamento de graves de psoríase crónica em placas em crianças e adolescentes a partir dos 4 anos de idade que tiveram uma resposta inadequada ou são inadequadas candidatos para a terapia tópica e phototherapies. hidradenitis suppurativa (hs)imraldi is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 e 5. a doença de crohn diseaseimraldi é indicado para o tratamento de activa moderada a grave doença de crohn, em doentes adultos que não responderam, apesar de um completo e adequado de terapia com corticosteróide e/ou imunossupressores; ou que são intolerantes ou tenham contra-indicações médicas para tais terapias. paediatric crohn's diseaseimraldi is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or haveulcerative colitisimraldi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisimraldi is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisimraldi is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whomcorticosteroid treatment is inappropriate. paediatric uveitisimraldi is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.